Duckworth David M.
Known title: Chief Financial OfficerCIK: 0001555047
Associated companies
Transaction History
| ACHC | ▲ Buy | Grant | 5,688 | $0 | 5/9/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 947 | $67K | 5/2/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 522 | $38K | 4/23/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 503 | $37K | 4/11/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 2,653 | $184K | 3/24/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 195,248 | $0 | 2/21/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 6,803 | $0 | 2/21/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 76,830 | $6.2M | 2/21/2023 | View on chart |
| ACHC | ▼ Sell | Open Market | 26,821 | $2.2M | 8/5/2022 | View on chart |
| ACHC | ▼ Sell | Open Market | 100 | $8K | 8/4/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 946 | $64K | 5/2/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 523 | $36K | 4/23/2022 | View on chart |
| ACHC | ▲ Buy | Grant | 5,128 | $0 | 4/11/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 2,653 | $171K | 3/24/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 694 | $42K | 3/2/2022 | View on chart |
| ACHC | ▲ Buy | Grant | 51,022 | $0 | 2/25/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 20,077 | $1.1M | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Acadia Healthcare Sets Q3 2026 Earnings Date
Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.
Acadia Healthcare Sets Q3 2026 Earnings Date. Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.